Sangamo Therapeutics (SGMO)
(Real Time Quote from BATS)
$0.50 USD
+0.01 (1.42%)
Updated Apr 25, 2024 03:14 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
SGMO 0.50 +0.01(1.42%)
Will SGMO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Other News for SGMO
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Biotech Roundtable: Who will bring the next CRISPR drug to market?
12 Health Care Stocks Moving In Friday's Intraday Session
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall